GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2015

Primary Completion Date

July 24, 2024

Study Completion Date

August 2, 2024

Conditions

Breast Cancer

Interventions

DRUG

Anastrozole

1 mg daily

DRUG

Letrozole

2.5 mg daily

Trial Locations (1)

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors

lead

University of Maryland, Baltimore

OTHER

NCT02095184 - GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | Biotech Hunter | Biotech Hunter